Mizuho Securities Assumes CASI Pharmaceuticals (CASI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CASI Hot Sheet
Price: $0.21 --0%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 1
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 1
Join SI Premium – FREE
Mizuho Securities analyst Mara Goldstein assumes coverage on CASI Pharmaceuticals (NASDAQ: CASI) with a Buy rating and a price target of $3.80.
For an analyst ratings summary and ratings history on CASI Pharmaceuticals click here. For more ratings news on CASI Pharmaceuticals click here.
Shares of CASI Pharmaceuticals closed at $0.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chardan Starts Vicore Pharma Holding (VCRE) at Buy
- H.C. Wainwright Starts Insmed (INSM) at Buy
- Bernstein SocGen Group Starts GlaxoSmithKline Pharmaceuticals (GLXO:IN) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Mara GoldsteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
